O
Oviva Therapeutics
A movement to improve women's experience of aging through biomedical research, development and advocacy
About Oviva Therapeutics
Oviva Therapeutics is a pioneering startup that is developing first-of-its-kind therapeutics to enhance ovarian function and extend the healthspan of women. The company operates in the healthcare and biotechnology market, specifically focusing on women's health. The business model of Oviva Therapeutics revolves around the research, development, and commercialization of novel therapeutics that target ovarian function and longevity.
Read full description
The company's primary clients are women who are experiencing or are at risk of age-related decline in ovarian function, which can lead to adverse health outcomes. Oviva Therapeutics aims to address this issue by developing innovative treatments that can extend the healthspan of women, thereby improving their overall health, well-being, and longevity.
The company generates revenue through the development and sale of these therapeutics. As the company's therapeutics are first-in-class, they have the potential to capture a significant market share in the women's health sector, providing a substantial revenue stream for the company.
Oviva Therapeutics is led by Daisy Robinton, PhD, who serves as the CEO and Co-Founder. The company is committed to not only developing effective therapeutics but also to elevating the broader conversation around women's health and building a coalition to drive this vision forward.
At a glance
- Status
- Acquired
- Founded
- 2021
- Headquarters
- New York City, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 55.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Femtech, Sustainable Development Goals, Biotech and Pharma, Longevity, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Apr 2025 | $0 | — | Granata Bio | ↗ |
| SEED✓Equity / VC | May 2022 | $12M | $46M | Cambrian BioPharma | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Oviva Therapeutics is 3.2K monthly website visits, up 100% over the last three months. Oviva Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cambrian BioPharma
Other known investors3 additional known investors
Granata Bio
Harvard Medical School
Massachusetts General Hospital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oviva Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oviva Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.